License Agreement

Takeda Signs an Exclusive License Agreement with Poseida for Novel Non-Viral In Vivo Gene Therapies

Shots: The parties will initially develop up to 6 in vivo gene therapy programs utilizing Poseida’s piggyBac, Cas-CLOVER & biodegradable nanoparticle technology for 6 liver & HSC directed indications. Takeda has an option to add 2 additional programs and is obligated to provide funding for all program’s R&D costs Poseida to receive $45M up front …

Takeda Signs an Exclusive License Agreement with Poseida for Novel Non-Viral In Vivo Gene Therapies Read More »

Bio-Thera and Hikma Sign an Exclusive Commercialization and License Agreement for BAT2206 (biosimilar, ustekinumab) in the US

Shots: Bio-Thera to receive $20M up front and $130M as development and commercial milestones and will be responsible for the development, manufacturing, and supply of BAT2206 Hikma get exclusive rights to commercialize the biosimilar in the US and received first-right-to-negotiate to add Europe (excluding CIS countries) BAT2206 is a mAb, that is a proposed biosimilar …

Bio-Thera and Hikma Sign an Exclusive Commercialization and License Agreement for BAT2206 (biosimilar, ustekinumab) in the US Read More »

AbbVie Terminates its License Agreement with Molecular Partners for Abicipar Pegol

Shots: AbbVie has terminated the license agreement for abicipar pegol to treat nAMD and DME. Additionally, Molecular Partners will reacquire the development and commercial rights of abicipar globally Molecular Partners will put a special committee to assess the program & figure out the next steps. Additionally, the companies will continue the ongoing discovery collaboration to …

AbbVie Terminates its License Agreement with Molecular Partners for Abicipar Pegol Read More »

Synaffix Signs a License Agreement with ProfoundBio for ADC Technologies

Shots: Synaffix is eligible to receive $246M upfront & milestones along with royalties on net sales. ProfoundBio to get non-exclusive license rights to use Synaffix’s ADC technologies for one therapeutic program to targets specific TAA & also retains license option rights to a second TAA The agreement will access Synaffix’s linker-payload technologies including GlycoConnect & …

Synaffix Signs a License Agreement with ProfoundBio for ADC Technologies Read More »

AcelRx Signs a License Agreement with Aguettant to Commercialize Dzuveo in EU and for Two Pre-Filled Syringe Products in US

Shots: Under Dzuveo agreement, AcelRx to receive ~$55M as an up front and commercial milestones in addition to 35% to 45% revenue share on net sales of Dzuveo. AcelRx will manufacture and supply Dzuveo while Aguettant gets the right to commercialize Dzuveo in the EU As per second agreement, Aguettant has the right to receive …

AcelRx Signs a License Agreement with Aguettant to Commercialize Dzuveo in EU and for Two Pre-Filled Syringe Products in US Read More »

Ipsen Signs an Exclusive WW License Agreement with IRLAB for Mesdopetam to Treat Parkinson Disease

Shots: IRLAB to receive ~$363M, including $28M as up front and ~$335M as development, regulatory and commercial milestones along with royalties on WW net sales of mesdopetam Ipsen get the exclusive WW rights to develop and commercialize mesdopetam (novel dopamine D3-receptor antagonist) which is currently being evaluated in P- IIb clinical trials for patients with …

Ipsen Signs an Exclusive WW License Agreement with IRLAB for Mesdopetam to Treat Parkinson Disease Read More »

Astellas Signs a License Agreement with ExCellThera for In Vitro Use of UM171 in Pluripotent Stem Cells

Shots: ExCellThera to receive up front, future contingent payments along with manufacturing and supply fees for the licensed molecules The collaboration validates the immense clinical and commercial potential of UM171 in additional fields of development The collaboration allows the ExcelThera to focus on clinical programs and commercial plans for ECT-001 cell therapy product along with …

Astellas Signs a License Agreement with ExCellThera for In Vitro Use of UM171 in Pluripotent Stem Cells Read More »

Biogen Signs a License Agreement with Innocare for Orelabrutinib to Treat Multiple Sclerosis

Shots: InnoCare to receive $125M as up front & is eligible to receive ~ $812.5M as development & commercial milestones, following the achievement of definite milestones along with royalties on sales of any product resulting from the collaboration Biogen to get exclusive rights for orelabrutinib to treat MS globally & other autoimmune diseases outside of …

Biogen Signs a License Agreement with Innocare for Orelabrutinib to Treat Multiple Sclerosis Read More »

Sanofi Signs ~$1B Agreement with Eureka & MSK for their Multiple Myeloma Candidate

Shots: Eureka and MSK are eligible to receive up front and ~$1B as development, regulatory and sales milestone along with royalties on net sales. Sanofi gets exclusive rights to the GPRC5D binder for non-CAR use Eureka discovered the GPRC5D binding domain using its E-ALPHA Abs discovery platform, under its collaboration with MSK Additionally, targeting GPRC5D …

Sanofi Signs ~$1B Agreement with Eureka & MSK for their Multiple Myeloma Candidate Read More »

Spero Therapeutics Enters into a License Agreement with Pfizer for SPR206 to Treat MDR Gram Negative Infections

Shots: Spero is eligible to receive $40M as an equity investment and ~$80M as development & sales milestones along with royalties on sales of SPR206 in licensed countries. Pfizer gets rights to develop, manufacture & commercialize SPR206 in ex-US & ex-Asia As per the 2019 licensing agreement with Spero, Everest Medicines has exclusive rights to …

Spero Therapeutics Enters into a License Agreement with Pfizer for SPR206 to Treat MDR Gram Negative Infections Read More »

Atea Pharma Secures $50M Milestone Payment with Roche in the Development of AT-527 for COVID-19

Shots: Atea Pharma achieved a milestone related to the development of AT-527 and is expecting to receive a related payment of $50M under its license agreement with Roche. The company believes that AT-527 is suitable for use in both pre-and post-exposure prophylactic settings and complementary to vaccines The companies are jointly developing AT-527 for the …

Atea Pharma Secures $50M Milestone Payment with Roche in the Development of AT-527 for COVID-19 Read More »

Mayo Clinic strikes remote patient monitoring partnership with NXgenPort

Mayo Clinic is ramping up activity in the remote patient monitoring arena. Its latest move is a collaboration with biomedical technology company NXgenPort, which will focus on an implantable catheter that can remotely monitor cancer patients for complications as they undergo treatment.

Phenomix Collaborates with Mayo Clinic for AI-Powered Obesity Phenotype Blood Test

Shots: The Phenomix’s MyPhenome test utilize phenotype-driven multi-omics technology to analyze genomics, metabolomics, and hormone levels and use AI-driven algorithmic tool to identify four specific obesity phenotypes, giving doctors the ability to prescribe more precise anti-obesity treatments The study showed that phenotype-specific obesity resulted in nearly double the weight loss over the treatment course of …

Phenomix Collaborates with Mayo Clinic for AI-Powered Obesity Phenotype Blood Test Read More »

Vertex Signs a License Agreement with Obsidian Therapeutics to Discover Regulated Gene Editing Therapies

Shots: Obsidian to receive $75M in equity, up front, research milestones and is eligible to receive ~$1.3B as research, development, regulatory, and commercial milestones across up to five potential programs. Additionally, Obsidian will receive royalties on sales of products that emerge from the collaboration Obsidian will deploy its cytoDRiVE platform to discover controllable genetic therapies …

Vertex Signs a License Agreement with Obsidian Therapeutics to Discover Regulated Gene Editing Therapies Read More »

Evotec Signs a License Agreement with Kazia Therapeutics for Clinical Development of EVT801

Shots: Evotec to receive a up front as well as research funding for biomarker development and CMC and is eligible to receive $361.21M as clinical & commercial milestones along with royalties on the net sales of EVT801, which will be shared with Sanofi (partner in the discovery and the development of EVT801) Kazia to get …

Evotec Signs a License Agreement with Kazia Therapeutics for Clinical Development of EVT801 Read More »

Eli Lilly Signs an Exclusive License Agreement with SciNeuro to Develop and Commercialize Alpha-synuclein Targeted Therapies in China

Shots: Lilly to receive up front, milestones, as well as royalties on the products developed and commercialize by SciNeuro. Lilly retains all rights outside Greater China SciNeuro to get an exclusive license to develop and commercialize alpha-synuclein targeted therapies in Greater China includes mainland China, Hong Kong, Macau, And Taiwan Alpha-synuclein directed therapies help to …

Eli Lilly Signs an Exclusive License Agreement with SciNeuro to Develop and Commercialize Alpha-synuclein Targeted Therapies in China Read More »

Cerecor Signs a Worldwide License Agreement with Kyowa Kirin for CERC-00

Shots: Kyowa Kirin to receive up front, regulatory & commercial milestones along with royalties and a share of sublicensing income. The company also has an option to retain rights in Japan Cerecor to get exclusive rights for the development, manufacturing and commercialization of CERC-00 for all indications globally including the US, EU and Japan The …

Cerecor Signs a Worldwide License Agreement with Kyowa Kirin for CERC-00 Read More »

Pfizer Signs a WW License Agreement with Pyxis to Develop and Commercialize Two ADC Candidates

Shots: Pfizer to receive an up front, equity in Pyxis and is eligible for development & commercial milestones as well as royalties on potential sales of ADCs Pyxis gets a WW license to develop and commercialize PYX-201 and PYX-203. Pfizer will continue to support the development and advancement of ADCs portfolio via an equity investment …

Pfizer Signs a WW License Agreement with Pyxis to Develop and Commercialize Two ADC Candidates Read More »

Pfizer Signs a WW License Agreement with Pyxis to Develop and Commercialize Two ADC Candidates

Shots: Pfizer to receive an up front, equity in Pyxis and is eligible for development & commercial milestones as well as royalties on potential sales of ADCs Pyxis gets a WW license to develop and commercialize PYX-201 and PYX-203. Pfizer will continue to support the development and advancement of ADCs portfolio via an equity investment …

Pfizer Signs a WW License Agreement with Pyxis to Develop and Commercialize Two ADC Candidates Read More »

Takeda Signs a License Agreement with Genevant to Develop Novel Nucleic Acid Therapeutics for Liver Fibrosis

Shots: Genevant to receive up to $600M up front and milestone as well as royalties on future product sales Takeda get exclusive rights to access Genevant’s LNP technology for a specified number of selected hepatic stellate cells targets The companies collaborated to discover, develop and commercialize the LNP-delivered nucleic acid therapeutics directed to previously inaccessible …

Takeda Signs a License Agreement with Genevant to Develop Novel Nucleic Acid Therapeutics for Liver Fibrosis Read More »

Merck KGaA Sign an Exclusive Worldwide License Agreement with Debiopharm for Xevinapant

Shots: Debiopharm to receive $226M up front, ~$853.7M as regulatory and commercial milestones along with royalties. The transaction is expected to close in early Q2’21 Merck KGaA get an exclusive right to develop and commercialize xevinapant globally, including in the US and will co-fund the ongoing P-III TrilynX study that involves assessing Xevinapant vs PBO …

Merck KGaA Sign an Exclusive Worldwide License Agreement with Debiopharm for Xevinapant Read More »

Bio-Techne Collaborates with Luminary to Utilize TcBuster in the Development of CAR-T cell Therapies

Shots: The companies signed a license agreement to deploy TcBuster for the manufacturing of gene-modified cell therapies Luminary gets a non-exclusive license for TcBuster and will use it in the LMY-920 program. Luminary plans to file an IND with the FDA in late 2021 The license agreement will allow Bio-Techne to increase its presence in …

Bio-Techne Collaborates with Luminary to Utilize TcBuster in the Development of CAR-T cell Therapies Read More »

Roche Concludes the License Agreement with Chugai for AT-527 to Treat COVID-19 in Japan

Shots: Chugai gets exclusive development and commercializing rights for AT-527 in Japan Earlier, Roche and Atea collaborated to jointly develop AT-527. If approved, Atea to distribute AT-527 in the US and Roche will be responsible for global manufacturing and distribution outside the US AT-527 is an investigational, oral, purine nucleotide prodrug, currently being evaluated in …

Roche Concludes the License Agreement with Chugai for AT-527 to Treat COVID-19 in Japan Read More »

P&G Signs a License Agreement with Rhinostics to Launch its Novel Nasal Swab into the Market for Rapid COVID-19 Testing and Address Supply Shortages

Shots: Rhinostics plans to register the P&G polypropylene nasal swab as a Class I Exempt medical device and will pursue Emergency Use Authorization for home collection with rPT-PCR testing for detection of SARS-CoV-2 infection Rhinostics Standard Nasal Swab is a polypropylene collection device developed in partnership with P&G for COVID-19 testing which provides sample concentration …

P&G Signs a License Agreement with Rhinostics to Launch its Novel Nasal Swab into the Market for Rapid COVID-19 Testing and Address Supply Shortages Read More »

MTPA and Aquestive Sign a License and Supply Agreement for Exservan (riluzole) to Treat ALS in the US

Shots: Aquestive will receive upfront, milestones, royalties on net sales for Exservan (oral film formulation) in the US and will earn revenue pursuant to the exclusive supply agreement MTPA to commercialize Exservan in the US while Aquestive will serve as the exclusive sole manufacturer and supplier for the product Exservan is an oral film formulation …

MTPA and Aquestive Sign a License and Supply Agreement for Exservan (riluzole) to Treat ALS in the US Read More »

Sanofi Signs a License Agreement with Biond for BND-22

Shots: Biond to receive $125M up front in cash and will be eligible to receive ~$1B+ as development, regulatory & commercial milestones, along with royalties on sales of the therapy Biond will lead P-Ia study of BND-22, assessing its safety & tolerability as a single agent and in combination with approved cancer therapies as well …

Sanofi Signs a License Agreement with Biond for BND-22 Read More »

Y-Biologics Signs a License Agreement with 3D Medicines for YBL-013 in the Territory of Greater China

Shots: Y-Biologics to receive ~$2M up front and eligible to receive ~$85M as development, regulatory, & commercialization milestones along with royalties on sales in the territory 3D Medicines will get an exclusive right to develop, manufacture, and commercialize YBL-013 in China with the expansion of collaboration in the US and other regions Both the companies …

Y-Biologics Signs a License Agreement with 3D Medicines for YBL-013 in the Territory of Greater China Read More »

Incyte Collaborates with Cellenkos for CK0804 to Treat Myelofibrosis

Shots: The companies collaborated to evaluate ruxolitinib in combination with CK0804 in patients with MF and plan to initiate a P-Ib study. Incyte will fund the study while operationalized by Cellenkos Cellenkos to receive $20M as licensing fee, ~$294.5M as development, regulatory and commercialization milestones along with royalties on sales of therapies, if approved. Incyte …

Incyte Collaborates with Cellenkos for CK0804 to Treat Myelofibrosis Read More »

Skyhawk Collaborates with Vertex to Discover and Develop Novel Small Molecules Modulating RNA Splicing for Serious Diseases

Shots: Skyhawk to receive $40M as upfront and is eligible to receive up to $2.2B as milestones along with royalties on sales. Vertex to get an option to exclusively license WW IP rights to candidates discovered and developed under the collaboration directed at serious diseases Following the exercise of its options, Vertex will be responsible …

Skyhawk Collaborates with Vertex to Discover and Develop Novel Small Molecules Modulating RNA Splicing for Serious Diseases Read More »

Eli Lilly Signs an Exclusive Agreement with Precision BioSciences on Genome Editing Research

Shots: Precision to receive $100M upfront, $35M as an equity investment and will receive $420M as milestones/ product along with royalties on sales of licensed products emerges from the collaboration Precision will lead to pre-clinical research and IND-enabling activities while Lilly will lead clinical development and commercialization and have the right to select up to …

Eli Lilly Signs an Exclusive Agreement with Precision BioSciences on Genome Editing Research Read More »

Roche Signs a License Agreement with Lead Pharma to Develop Oral Therapies for Immune-Mediated Diseases

Shots: Lead Pharma receives ~$11.86M upfront and is eligible to receive funding and ~$307.9 as research, development, regulatory and commercial milestones along with royalties on sales of small molecules The companies will collaborate in research activities up to the selection of a pre-clinical candidate after which Roche will be responsible for the development and global …

Roche Signs a License Agreement with Lead Pharma to Develop Oral Therapies for Immune-Mediated Diseases Read More »

Eli Lilly Signs a License Agreement with Seed Therapeutics for Protein Degradation-Based Therapies

Shots: Seed Therapeutics to receive $10M upfront, $10M equity investment, ~$780M as pre/clinical development, regulatory & commercial milestones along with royalties on net sales of products that emerges from the collaboration Seed utilizes molecular glue protein degradation technology to develop potential new therapies The agreement allows Seed to advance its platform to deliver new molecules …

Eli Lilly Signs a License Agreement with Seed Therapeutics for Protein Degradation-Based Therapies Read More »

Qiagen Collaborate with TScan to Develop T Cell-Based COVID-19 Test

Shots: TScan signs exclusive research and option to license agreement with Qiagen to develop T cell-based laboratory tests for detecting prior exposure to the SARS-CoV-2 Qiagen gets an option to license the rights and IP for several of TScan discovered immunodominant T cell targets, associated sequences and relevant data for the development and commercialization of …

Qiagen Collaborate with TScan to Develop T Cell-Based COVID-19 Test Read More »

CStone Signs a License Agreement with LegoChem for LCB71 to Treat Multiple Cancer Indications

Shots: LCB to receive $10 M as upfront, and up to $353.5M as cumulative milestone payments along with royalties on sales of LCB71. CStone get an exclusive global right to lead the development and commercialization of LCB71 outside the Republic of Korea The collaboration adds the first ADC to CStone’s development pipeline, bolstering its precision …

CStone Signs a License Agreement with LegoChem for LCB71 to Treat Multiple Cancer Indications Read More »

Novartis Signs an Option and License Agreement with Molecular Partners to Develop Two DARPin Therapies for COVID-19

Shots: Molecular Partners to receive $65.8M as up front, including equity, and will receive $164.7M as an option payment for both MP0420 and MP0423 along with royalties on sales of therapies. Novartis to get an option to in-license global rights of MP0420 and MP0423 During the option period, Molecular Partners will conduct a P-I study …

Novartis Signs an Option and License Agreement with Molecular Partners to Develop Two DARPin Therapies for COVID-19 Read More »

Novo Nordisk Signs a License Agreement with Chugai for Antibody Engineering Technologies

Shots: Chugai will receive an upfront, development milestone and royalties if the compound is launch as an approved Ab drug. Additionally, Chugai will receive a fee for technology access Novo Nordisk to get the rights to use several Chugai Ab engineering technologies for their research activities and optional right for the development and marketing of …

Novo Nordisk Signs a License Agreement with Chugai for Antibody Engineering Technologies Read More »

Roche Signs a License Agreement with Dyno to Develop AVV Gene Therapy for ~$1.8B

Shots: Dyno to receive upfront and is eligible to receive ~$1.8B milestones including development and commercial milestones along with royalties on any product emerges during the collaboration Dyno will be responsible for the design of novel AAV capsids with improved functional properties for gene therapy while Roche and Spark will conduct preclinical, clinical, and commercialization …

Roche Signs a License Agreement with Dyno to Develop AVV Gene Therapy for ~$1.8B Read More »

BMS Signs an Exclusive Worldwide License Agreement with Dragonfly Therapeutics for DF6002

Shots: Dragonfly to receive $475M as up front and is eligible to receive development, regulatory and commercial milestones in addition to 24% royalties on global sales of the therapy. BMS to get exclusive WW license to Dragonfly’s IL-12 investigational immunotherapy program, including its extended half-life cytokine DF6002 BMS will be responsible for the development & …

BMS Signs an Exclusive Worldwide License Agreement with Dragonfly Therapeutics for DF6002 Read More »

Solasia Signs a License Agreement with Isofol to Develop and Commercialize Arfolitixorin for mCRC in Japan

Shots: Isofol to receive $100M as up front, development, regulatory and commercial milestones, and clinical development cost and is eligible to receive royalties on sales of the therapy and retain its right to the therapy in ROW Solasia will lead clinical development activities in Japan and will be responsible for registrational filing and approval in …

Solasia Signs a License Agreement with Isofol to Develop and Commercialize Arfolitixorin for mCRC in Japan Read More »

AstraZeneca Signs a License Agreement with Redx Pharma for RXC006 to Treat Idiopathic Pulmonary Fibrosis

Shots: Redx to receive $17M in early payment by the time of successful commencement of a P-I study, $360M as development, a regulatory and commercial milestone along with royalties on sales of the RXC006 AstraZeneca to get an exclusive global license to further develop & commercialize RXC006 targeting fibrotic diseases including IPF Redx continues to …

AstraZeneca Signs a License Agreement with Redx Pharma for RXC006 to Treat Idiopathic Pulmonary Fibrosis Read More »